within Pharmacolibrary.Drugs.ATC.J;

model J01MA24
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 7.0 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 800 / 1000000,
    adminCount     = 1,
    Vd             = 0.0148,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Levonadifloxacin is a broad-spectrum, novel benzoquinolizine fluoroquinolone antibiotic used primarily for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital-acquired pneumonia. It is effective against Gram-positive pathogens including methicillin-resistant Staphylococcus aureus (MRSA). Levonadifloxacin has been approved for clinical use in India.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for healthy adult subjects following intravenous administration.</p><h4>References</h4><ol><li><p>Bhagwat, SS, Nandanwar, M, Kansagara, A, Patel, A, Takalkar, S, Chavan, R, Periasamy, H, Yeole, R, Deshpande, PK, Bhavsar, S, Bhatia, A, Ahdal, J, Jain, R, &amp; Patel, M (2019). Levonadifloxacin, a Novel Broad-Spectrum Anti-MRSA Benzoquinolizine Quinolone Agent: Review of Current Evidence. <i>Drug design, development and therapy</i> 13 4351–4365. DOI:<a href=&quot;https://doi.org/10.2147/DDDT.S229882&quot;>10.2147/DDDT.S229882</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31920285/&quot;>https://pubmed.ncbi.nlm.nih.gov/31920285</a></p></li><li><p>Mehta, Y, Mishra, KC, Paliwal, Y, Rangappa, P, Sinha, S, &amp; Bhapkar, S (2022). Meeting the Unmet Need in the Management of MDR Gram-Positive Infections with Oral Bactericidal Agent Levonadifloxacin. <i>Critical care research and practice</i> 2022 2668199–None. DOI:<a href=&quot;https://doi.org/10.1155/2022/2668199&quot;>10.1155/2022/2668199</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36785544/&quot;>https://pubmed.ncbi.nlm.nih.gov/36785544</a></p></li><li><p>Bhatia, A, Mastim, M, Shah, M, Gutte, R, Joshi, P, Kumbhar, D, Periasamy, H, Palwe, SR, Chavan, R, Bhagwat, S, Patel, M, Llorens, L, &amp; Friedland, HD (2020). Efficacy and Safety of a Novel Broad-Spectrum Anti-MRSA Agent Levonadifloxacin Compared with Linezolid for Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Openlabel, Randomized Study. <i>The Journal of the Association of Physicians of India</i> 68(8) 30–36. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32738837/&quot;>https://pubmed.ncbi.nlm.nih.gov/32738837</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J01MA24;
